Samsung Medical Center-Lymphoma Cohort Study-II
NCT01877109 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1358
Last updated 2017-10-27
Summary
The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
Conditions
Sponsors & Collaborators
-
Samsung Medical Center
lead OTHER
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-02-01
- Primary Completion
- 2017-02-28
- Completion
- 2017-02-28
Countries
- South Korea
Study Locations
More Related Trials
-
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
NCT02691351 ·Status: COMPLETED
-
Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma
NCT01341119 ·Status: COMPLETED
-
Bortezomib Maintenance in High Risk DLBCL
NCT01965977 ·Status: UNKNOWN ·Phase: PHASE2
-
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
NCT06552572 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
NCT03977623 ·Status: UNKNOWN
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea
NCT04048395 ·Status: UNKNOWN
-
Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma
NCT04061850 ·Status: COMPLETED
-
Gemcitabine for Marginal Zone Lymphoma
NCT00337259 ·Status: TERMINATED ·Phase: PHASE2
-
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
NCT02445404 ·Status: UNKNOWN ·Phase: PHASE2
-
CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
NCT06202885 ·Status: ACTIVE_NOT_RECRUITING
-
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
NCT05260619 ·Status: RECRUITING ·Phase: PHASE2
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
NCT03578198 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT01676558 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573 ·Status: RECRUITING ·Phase: NA
-
Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma
NCT01202448 ·Status: COMPLETED ·Phase: NA
-
Watch and Wait or Worry and Wait in Indolent Lymphoma
NCT07173790 ·Status: ENROLLING_BY_INVITATION
-
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma
NCT02060435 ·Status: COMPLETED
-
Gemcitabine in NK/T Cell Lymphoma
NCT01660568 ·Status: COMPLETED
-
Navigating the Clinical Research Process for Lymphoma
NCT06070246 ·Status: NOT_YET_RECRUITING
-
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
NCT01562990 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
NCT01792310 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05751798 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
NCT05788081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2